President Trump makes an announcement at the White House — 10/10/2025

Key Concepts

• Most Favored Nations (MFN) Pricing: A policy ensuring that Americans pay no more for prescription drugs than the lowest price paid by any other country in the world for the same drug.
• Trump RX (trumprx.gov): An online platform where Americans can find information about heavily discounted prescription drugs, aiming to eliminate middlemen and provide direct access to MFN costs.
• Onshoring/Reshoring Manufacturing: The process of bringing pharmaceutical research, development, and production facilities back to the United States to enhance national security, economic stability, and supply chain resilience.
• Tariffs as Leverage: The use of import duties as a strategic tool to incentivize foreign companies to invest and manufacture within the United States and agree to MFN pricing.
• IRA Drug Price Negotiations: A reference to the Inflation Reduction Act's provisions for Medicare to negotiate drug prices, which the current administration critiques as ineffective, claiming it led to higher costs for most drugs.
• Active Pharmaceutical Ingredients (API): The biologically active component of a drug product, crucial for drug manufacturing.
• Antibody Drug Conjugates (ADCs): A class of highly potent biopharmaceutical drugs designed as a targeted therapy for treating cancer, often referred to as "smart chemotherapy."
• Presidential Medal of Freedom: The highest civilian award in the United States, awarded by the President.
• Merit System: A system where appointments and promotions are based on demonstrated ability and performance rather than political affiliation or other non-merit factors.

---

Historic Drug Price Reduction Initiative

President Trump announced a "historic achievement" in lowering drug prices for all Americans, building on efforts to reduce costs across various sectors, including groceries and oil. He noted that oil prices have significantly decreased, breaking $60 a barrel and projected to fall below $2 a gallon soon, representing a 70% reduction from a year ago. This reduction in oil prices is expected to lower costs across the economy.

The central announcement was a commitment from AstraZeneca, the largest pharmaceutical manufacturer in the United Kingdom, to offer major discounts on its vast catalog of prescription drugs to Americans. This commitment includes a Most Favored Nations (MFN) pricing clause, meaning Americans will pay the lowest price for these drugs available anywhere in the world. President Trump stated that he had initiated this policy during his first term but was unable to fully implement it due to a "rigged election."

The AstraZeneca Partnership and Most Favored Nations (MFN) Pricing

Specifics of the Deal: AstraZeneca has committed to offering all its prescription medications to Medicaid at MFN prices, a move expected to save American taxpayers "hundreds of millions of dollars each year." President Trump contrasted this with a modest 1/8 of 1% drug price reduction achieved in his first term, now projecting reductions of "100%, 400%, 600%, a thousand percent in some cases." These significant reductions are anticipated to have a "huge impact" on programs like Social Security, Medicare, and Medicaid.

Trump RX Platform: AstraZeneca will list many of its most popular drugs online at trumprx.gov, a platform designed to provide heavily reduced MFN costs directly to consumers. Dr. Oz later clarified that this platform will serve as a marketplace, making information available for consumers to find the right place to buy medications without middlemen. As an example of the expected discounts, inhalers for COPD and asthma, as well as certain diabetic medications, are projected to see an average price reduction of 654%. Furthermore, all new medications AstraZeneca introduces to the American market going forward will also be sold at these heavily discounted rates.

Investment in US Manufacturing and R&D: Beyond price reductions, AstraZeneca has pledged to invest $50 billion in the United States over the next five years for research and development of new drugs and to establish onshore manufacturing facilities. This includes a new plant that broke ground yesterday in Charlottesville, Virginia, which is expected to create 3,600 jobs initially. This investment is hailed as a "tremendous victory for Virginia and for American patients."

Strategic Rationale and Leverage

Critique of Previous Drug Price Negotiations (IRA): Secretary Robert F. Kennedy Jr. highlighted the perceived failures of the Inflation Reduction Act (IRA) drug price negotiations under the previous administration. He stated that while Democrats claimed a 22% reduction on 10 negotiated drugs, an agency review revealed that Medicare was actually paying more for eight of those drugs, an equal price for one, and only a 2% discount on the tenth. This contrasted sharply with President Trump's long-standing vision to address the unfairness of Americans paying three, four, five, or even ten times more for the same drugs than European countries, even for drugs manufactured in the US.

The Role of Tariffs: A key argument presented by the administration, particularly by Secretary Kennedy and President Trump, was that the ability to secure these deals stemmed from the leverage provided by tariffs. President Trump explicitly stated that these pharmaceutical companies would not have come to the table without the imposition of tariffs. He noted that if companies build in the US, they face no tariffs, creating a strong incentive for onshoring manufacturing. Pascal Soriot, AstraZeneca's CEO, reportedly acknowledged behind the scenes that tariffs were a significant factor in their decision.

Rebalancing Global Innovation Costs: Secretary Kennedy and Pascal Soriot emphasized that the US, despite having only 4.2% of the world's population, accounts for 70% of global pharmaceutical revenues and pays for 80-90% of pharmaceutical innovation. This imbalance meant the rest of the world was "free-riding" on American innovation. The MFN policy and the investment commitments aim to achieve "equalization," ensuring other wealthy nations contribute their fair share to the costs and risks associated with pharmaceutical R&D, making the global business model more sustainable.

Stakeholder Perspectives

• Secretary Robert F. Kennedy Jr.: Described the deal as an "extraordinary" and "monumental" achievement, fulfilling President Trump's 20-year dream. He outlined the President's three demands: MFN prices, not bankrupting companies (to maintain US innovation), and reshoring the industry for national security and economic purposes. He praised Pascal Soriot for understanding the need for global participation in innovation costs.
• Dr. Oz: Characterized the initiative as turning "the art of the deal into the art of the heal," bringing "peace of mind" to Americans struggling with medication costs. He highlighted the scalability of the MFN approach, following a similar deal with Pfizer, and stressed that the President's resolve made other countries realize "the jig was up." He detailed the five deal points, including the launch of Trump RX, massive discounts for specific drug categories, MFN for Medicaid and all new drugs, and the onshoring of manufacturing.
• Pascal Soriot (AstraZeneca CEO): Expressed excitement about AstraZeneca's commitment to President Trump's vision of lowering medicine prices while maintaining America's role as a biopharmaceutical innovation powerhouse. He thanked the President and his team for their "collaborative and trusting approach." Soriot outlined the "wins" for American patients (improved access, lower costs), the economy and taxpayers (rebalancing R&D costs), and state budgets (immediate Medicaid price reductions). He reiterated AstraZeneca's $50 billion investment in US manufacturing and R&D, including expanding facilities in Texas, Boston (Kendall Square), and Rockville, Maryland, and the $4.5 billion investment in Charlottesville, Virginia, for manufacturing Active Pharmaceutical Ingredients (API) and Antibody Drug Conjugates (ADCs) for cancer treatment. He also thanked Secretary Lutnik for a three-year tariff exemption to localize remaining products.
• Governor Glenn Youngkin (Virginia): Described the initiative as a "step-function change" for Virginians and Americans, moving from opaque pricing to direct-to-consumer access. He emphasized that MFN ensures "America must come first" and Americans get the best pricing. For Virginia, the deal could save $150-450 million annually from its $1.5 billion Medicaid pharmaceutical expenditure, which he believes should be returned to taxpayers. He underscored the national security implications of reshoring critical supply chains and the economic boost from the $4.5 billion investment in Virginia, translating to an estimated $3-4 of economic impact for every dollar spent and creating 3,600 jobs. Virginia has secured nearly $10 billion in commitments for new pharmaceutical manufacturing.

Broader Economic and National Security Implications

The speakers consistently linked the drug pricing initiative to broader economic and national security goals. The onshoring of pharmaceutical manufacturing, particularly for critical components like APIs and ADCs, is seen as vital for enhancing national security and reducing reliance on foreign supply chains. The investments by AstraZeneca and other companies contribute to job creation and economic growth, with President Trump claiming $18 trillion in commitments and investments in the US over eight months, a figure he contrasted sharply with the previous administration's record.

Additional Policy Discussions (Q&A)

The press conference also touched upon several other policy areas:

• US-China Relations and Tariffs: President Trump confirmed that tariffs were instrumental in bringing pharmaceutical companies to the negotiating table. Regarding China, he stated that he had not canceled a meeting with President Xi but was unsure if it would happen. He criticized China for "hitting the world" with export controls, which he viewed as a response to their actions and aimed globally. He indicated that other export control targets could include airplanes and airplane parts.
• Middle East Peace Deal (Gaza): President Trump announced a Gaza deal, stating that Israeli Prime Minister wanted it and it was a "great deal for everybody." He confirmed that hostages would return on Monday, and approximately 28 bodies were being unearthed. He claimed to have seen dancing in the streets in Israel, Qatar, Saudi Arabia, UAE, and Egypt. He plans to visit Israel (speaking at the Knesset) and Egypt. He expressed confidence the ceasefire would hold, citing Hamas's loss of 58,000 people as "big retribution." He also mentioned the establishment of a "Board of Peace," which he was asked to chair, and noted that Iran and Russia (President Putin) fully support the deal.
• Government Shutdown and Layoffs: President Trump stated that "reductions in force" (layoffs) had begun due to the government shutdown, which he attributed to Democrats. He indicated that these layoffs would be "Democrat oriented" and "a lot" of people would be affected, with numbers to be announced soon. He linked this to Democrats' alleged desire to allocate $1.5 trillion to illegal immigrants, while claiming his administration had achieved "zero people coming in illegally" for four months, with all entries now being legal.
• Nobel Peace Prize: President Trump commented on the Nobel Peace Prize announcement, noting that he had made eight peace deals during his tenure, including resolving long-standing conflicts (e.g., India/Pakistan, Congo/Rwanda) often using trade and tariffs as leverage. He mentioned that the recent Nobel laureate (in the context of Venezuela) had called him, stating she accepted the award in his honor because he deserved it, having saved "millions of lives."
• Immigration and Domestic Crime: President Trump affirmed that ICE was making targeted arrests of criminals at courthouses. He claimed that Washington D.C., once unsafe, had become "one of the safest places" due to the deployment of "not politically correct military" based on a merit system. He cited similar improvements in Memphis and announced plans to address crime in Chicago, criticizing its governor and mayor for their handling of the city's high murder rates (4,000 killed over a short period). He also criticized the situation in Portland, Oregon, describing it as "burning down" and "almost an insurrection."

Conclusion: Main Takeaways

The core message of the event was the administration's success in leveraging its policies, particularly tariffs, to secure unprecedented drug price reductions for Americans through the Most Favored Nations (MFN) pricing model. The partnership with AstraZeneca, including its $50 billion investment and the creation of Trump RX, signifies a major step towards making life-saving medications more affordable and accessible while simultaneously reshoring critical pharmaceutical manufacturing to the US. This initiative is presented as a multi-faceted victory, benefiting American patients, taxpayers, state budgets, and national security, by rebalancing global innovation costs and strengthening domestic supply chains. The President also used the platform to highlight broader economic achievements and address other pressing policy issues, reinforcing his administration's approach to domestic and international affairs.